akusherstvoObstetrics, Gynecology and ReproductionАкушерство, Гинекология и Репродукция2313-73472500-3194IRBIS LLC10.17749/2313-7347.2015.10.1.075-083akusherstvo-37Research ArticleREVIEW ARTICLEНАУЧНЫЙ ОБЗОРCURRENT OPINIONS CONCERNING THE PATHOGENESIS OF EPITHELIAL OVARIAN CANCER AND NEW DIAGNOSTIC APPROACHES TO THE DISEASEСОВРЕМЕННЫЕ ВЗГЛЯДЫ НА ПАТОГЕНЕЗ И ВОЗМОЖНОСТИ ДИАГНОСТИКИ ЭПИТЕЛИАЛЬНОГО РАКА ЯИЧНИКОВСолоповаА. Е.SolopovaA. E.

к.м.н., доцент кафедры лучевой диагностики и лучевой терапии лечебного факультета Первого МГМУ им. И.М. Сеченова. Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119991. 

docent at the Department of Radiology of the First Moscow Medical Sechenov University. Address: Trubetskaya, 8, str. 2, Moskva, Russia, 119991

dr.solopova@mail.ruЧащинА. А.ChashchinA. A.

интерн кафедры акушерства и гинекологии медико-профилактического факультета Первого МГМУ им. И.М. Сеченова. Адрес: г. Москва, пр. Маршала Жукова, д. 66, кв. 55, Москва, Россия, 123103

MD, intern of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine First Moscow Medical Sechenov University. Address: Marshal Zhukov av., 66-55, Moscow, Russia, 123103

alexchashchin@gmail.comСолоповаА. Г.SolopovaA. G.

д.м.н., профессор кафедры акушерства и гинекологии медико-профилактического факультета Первого МГМУ им. И.М. Сеченова. Адрес: ул. Земляной Вал, 62, стр. 1, Москва, Россия, 109004.

MD, professor of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive Medicine First Moscow Medical Sechenov University. Address: ul. Zemlyanoi Val, 62-1, Moscow, Russia, 109004

antoninasolopova@yandex.ruМакацарияА. Д.MakatsariyaA. D.

д.м.н., член-корреспондент РАН, профессор, заведующий кафедрой акушерства и гинекологии медико-профилактического факультета Первого МГМУ им. И.М. Сеченова. Адрес: ул. Трубецкая, 8, стр. 2, Москва, Россия, 119048. Тел.: +7 (495) 788-58-40.

MD, corresponding member of the Russian Academy of Sciences, Professor, Head of the Department of Obstetrics and Gynecology, Faculty of Medical and Preventive, First Moscow State Medical Sechenov University. Address: ul. Trubetskaya, 8, str. 2, Moskva, Russia, 119048. Tel.: +7 (495) 788-58-40.

gemostasis@mail.ruГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава РФ, МоскваРоссияFirst Moscow State Medical Sechenov University of the Ministry of Health Russian FederationRussian Federation2016050620161017583Copyright © Solopova A.E., Chashchin A.A., Solopova A.G., Makatsariya A.D., 20162016Солопова А.Е., Чащин А.А., Солопова А.Г., Макацария А.Д.Solopova A.E., Chashchin A.A., Solopova A.G., Makatsariya A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gynecology.su/jour/article/view/37

Because of high mortality rate, the lack of effective methods for early diagnosis and limited success in treatment, ovarian cancer of epithelial origin is a major problem in gynecological oncology. These problems are largely due to our lack of the disease etiopathogenesis understanding. This article attempts to summarize recent data on the sources and the development of the cancer process in the ovary as well as to introduce modern approaches to the diagnosis of this type of malignancy.

В связи с высокой летальностью, отсутствием эффективных методов ранней диагностики и ограниченными успехами в лечении рака яичников эпителиального происхождения это заболевание является одной из основных проблем в онкогинекологии. Данные сложности во многом обусловлены недостаточным пониманием этиопатогенеза данного заболевания. В настоящей статье сделана попытка обобщить последние данные об источниках и развитии ракового процесса в яичнике, а также представить современные подходы к диагностике этого вида злокачественных новообразований.

Рак яичниковпатогенезскринингтехнологии визуализацииМРТOvarian cancerpathogenesisscreeningimaging technologiesMRTReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 г. (заболеваемость и смертность). М. 2015; 250 с. / Kaprin A.D., Starinskii V.V., Petrova G.V. [Malignancies in Russia in 2013 (morbidity and mortality) (in Russian)]. Moscow. 2015; 250 s.Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 г. (заболеваемость и смертность). М. 2015; 250 с. / Kaprin A.D., Starinskii V.V., Petrova G.V. [Malignancies in Russia in 2013 (morbidity and mortality) (in Russian)]. Moscow. 2015; 250 s.Barakat R.R., Markman M., Randall M. Principles and practice of gynecologic oncology. – 5th ed. Philadelphia. 1088 р.Barakat R.R., Markman M., Randall M. Principles and practice of gynecologic oncology. – 5th ed. Philadelphia. 1088 р.Bell D. et al. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011; 474.7353: 609-615.Bell D. et al. Integrated Genomic Analyses of Ovarian Carcinoma. Nature. 2011; 474.7353: 609-615.Bereck L., Neville N. (eds) Berek&Hacker’s gynecologic oncology, 5th edn. Philadelphia. 2010; 912 p.Bereck L., Neville N. (eds) Berek&Hacker’s gynecologic oncology, 5th edn. Philadelphia. 2010; 912 p.Borley J., Wilhelm-Benartzi C. et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015 May; 122 (6): 843-9.Borley J., Wilhelm-Benartzi C. et al. Radiological predictors of cytoreductive outcomes in patients with advanced ovarian cancer. BJOG. 2015 May; 122 (6): 843-9.Cannistra S.A. Cancer of the Ovary. NEJM. 2004; 351:2519-29.Cannistra S.A. Cancer of the Ovary. NEJM. 2004; 351:2519-29.Chan John K., Teoh D., Hu Jessica M. et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncology. 2008; 109: 370-376.Chan John K., Teoh D., Hu Jessica M. et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecologic Oncology. 2008; 109: 370-376.Chen Y.M., Chen T., Zee C.S. et al. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center.Chen Y.M., Chen T., Zee C.S. et al. Is there an impact of 18F-FDG PET/CT on the surveillance and clinical management of recurrent ovarian cancer? Research based on a large sample in a single PET/CT center.Ferlay J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013; 49 (6): 1374-1403.Ferlay J. et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. European Journal of Cancer. 2013; 49 (6): 1374-1403.Fischerova D. et al. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. The Oncologist. 2012; 17: 1515-1533.Fischerova D. et al. Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. The Oncologist. 2012; 17: 1515-1533.Forstner Rosemarie, Meissnitzer Matthias W., Schlattau Alexander & Spencer John A. MRI in ovarian cancer Imaging Med. 2012; 4 (1): 59-75.Forstner Rosemarie, Meissnitzer Matthias W., Schlattau Alexander & Spencer John A. MRI in ovarian cancer Imaging Med. 2012; 4 (1): 59-75.Fujiwara Hiroyuki, Suzuki Mitsuaki et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women Tumor Biol. 2015; 36: 1045-1053.Fujiwara Hiroyuki, Suzuki Mitsuaki et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women Tumor Biol. 2015; 36: 1045-1053.Griffin Nyree et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? EurRadiol. 2009; 19: 230-235.Griffin Nyree et al. Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? EurRadiol. 2009; 19: 230-235.Gusehet S.H. et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecologic Oncology. 2014; 132: 649-653.Gusehet S.H. et al. Transitional cell carcinoma of the ovary: A case-control study. Gynecologic Oncology. 2014; 132: 649-653.Hebel C.B., Behrendt F.F. et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion ofrecurrent ovarian cancer. Eur J Radiol. 2014 Mar; 83 (3): 463-7.Hebel C.B., Behrendt F.F. et al. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion ofrecurrent ovarian cancer. Eur J Radiol. 2014 Mar; 83 (3): 463-7.Iyer V.R., Lee S.I. MRI, CT, and PET/CT for Ovarian Cancer Detection and adnexal Lesion Characterization. AJR. February 2010; 194.Iyer V.R., Lee S.I. MRI, CT, and PET/CT for Ovarian Cancer Detection and adnexal Lesion Characterization. AJR. February 2010; 194.Kinkel K., Lu Y., Mehdizade A., Pelte M.F., Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization – meta-analysis and Bayesian analysis. Radiology. 2005; 236: 85-94.Kinkel K., Lu Y., Mehdizade A., Pelte M.F., Hricak H. Indeterminate ovarian mass at US: incremental value of second imaging test for characterization – meta-analysis and Bayesian analysis. Radiology. 2005; 236: 85-94.Klatt E.C. Robbins and Cotran Atlas ofPathology. Elsevier, 3rd edition. 2015; 552 p.Klatt E.C. Robbins and Cotran Atlas ofPathology. Elsevier, 3rd edition. 2015; 552 p.Kurman R.J. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – Shifting the paradigm Human Pathology. 2011; 42: 918-931.Kurman R.J. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer – Shifting the paradigm Human Pathology. 2011; 42: 918-931.Kurman R.J. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J SurgPathol. 2010 Mar; 34 (3): 433-443.Kurman R.J. The Origin and Pathogenesis of Epithelial Ovarian Cancer – a Proposed Unifying Theory. Am J SurgPathol. 2010 Mar; 34 (3): 433-443.Kyriazi S., Kaye Stan B., Nandita M. de Souza Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nature reviews. 2010 Jul; 7 (7): 381-93.Kyriazi S., Kaye Stan B., Nandita M. de Souza Imaging ovarian cancer and peritoneal metastases – current and emerging techniques. Nature reviews. 2010 Jul; 7 (7): 381-93.Ledermann J. A., Raja F.A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013; 24 (6): vi24-vi32.Ledermann J. A., Raja F.A. et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2013. Ann Oncol. 2013; 24 (6): vi24-vi32.Lee Y., Miron A., Drapkin R. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-3569.Lee Y., Miron A., Drapkin R. et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007; 211: 26-3569.MacKintosh M.L., Rahim R., et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014 Jul; 34 (5): 424-8.MacKintosh M.L., Rahim R., et al. CT scan does not predict optimal debulking in stage III-IV epithelial ovarian cancer: a multicentre validation study. J Obstet Gynaecol. 2014 Jul; 34 (5): 424-8.Medeiros L.R. Accuracy of Ultrasonography With Color Doppler in Ovarian Tumor: A Systematic Quantitative ReviewInternational Journal of Gynecological Cancer. February 2009; 19 (2): 230-236.Medeiros L.R. Accuracy of Ultrasonography With Color Doppler in Ovarian Tumor: A Systematic Quantitative ReviewInternational Journal of Gynecological Cancer. February 2009; 19 (2): 230-236.Menon Usha et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J ClinOncol. 2015; 33.Menon Usha et al. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J ClinOncol. 2015; 33.Nucci M. R. Olivia Esther Gynecologic Pathology Elsevier Churchill Livingstone. 2009; 709 р.Nucci M. R. Olivia Esther Gynecologic Pathology Elsevier Churchill Livingstone. 2009; 709 р.Scully R.E., Young R.H., Clement P.B. Tumors of the Ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Atlas of tumor pathology, 3 rd Series, Fascicle 23, Washington, DC: Armed Forces Institute of Pathology. 1998: 1-168.Scully R.E., Young R.H., Clement P.B. Tumors of the Ovary, maldeveloped gonads, fallopian tube and broad ligament. In: Atlas of tumor pathology, 3 rd Series, Fascicle 23, Washington, DC: Armed Forces Institute of Pathology. 1998: 1-168.Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J GynecolPathol. 2004; 23: 41-4.Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J GynecolPathol. 2004; 23: 41-4.Seidman J.D., Yemelyanova A., Zaino R.J., Kurman R.J. The fallopian tube–peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol. 2010; 30: 4-11.Seidman J.D., Yemelyanova A., Zaino R.J., Kurman R.J. The fallopian tube–peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol. 2010; 30: 4-11.Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J Clin. 2015; 65 (5): 29.Siegel R.L., Miller K.D., Jemal A. Cancer statistics. CA Cancer J Clin. 2015; 65 (5): 29.Spencer J.A. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. EurRadiol. 2010; 20: 25-35.Spencer J.A. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. EurRadiol. 2010; 20: 25-35.Stiekema A. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic Oncology. 2015 Mar; 136 (3): 562-6.Stiekema A. et al. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin. Gynecologic Oncology. 2015 Mar; 136 (3): 562-6.Thabet Ashraf et al. Image-Guided Ovarian Mass Biopsy. Efficacy and Safety J Vasc Interv Radiol. 2014; 25: 1922-1927.Thabet Ashraf et al. Image-Guided Ovarian Mass Biopsy. Efficacy and Safety J Vasc Interv Radiol. 2014; 25: 1922-1927.Thomassin-Naggara I., Balvay D. et al. Added Value of Assessing Adnexal Masses with Advanced MRI Techniques. BioMed Research International. 2015; Article ID 785206, 10 p.Thomassin-Naggara I., Balvay D. et al. Added Value of Assessing Adnexal Masses with Advanced MRI Techniques. BioMed Research International. 2015; Article ID 785206, 10 p.Van Gorp Toon et al Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer. 2012; 48: 1649-1656.Van Gorp Toon et al Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer. 2012; 48: 1649-1656.Wagner U., Harter P. et al. S3-Leitline Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. 2013, 103 s.Wagner U., Harter P. et al. S3-Leitline Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. 2013, 103 s.Wilkinson N., Pathology of the Ovary, Fallopian Tube and Peritoneum. Sprienger- Verlag. London. 2014; 524 р.Wilkinson N., Pathology of the Ovary, Fallopian Tube and Peritoneum. Sprienger- Verlag. London. 2014; 524 р.Yamamoto S., Tsuda H. et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Modern Pathology. 2012; 25: 615-624.Yamamoto S., Tsuda H. et al. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Modern Pathology. 2012; 25: 615-624.

The authors declare that there are no conflicts of interest present.